MDI Bridge transforms any standard generic asthma or COPD inhaler into a cellular-connected acoustic diagnostic device. We bridge patients, pulmonologists, and insurers—automating Medicare/Private RTM reimbursement while cutting preventable hospitalizations.
Low exacerbation probability (4.2%). Controller technique verified.
Legacy connected inhalers failed because they locked patients into expensive proprietary drugs or required elderly COPD patients to pair Bluetooth apps. MDI Bridge is drug-agnostic, cellular-native, and reimbursement-first.
Clips onto 85%+ of existing prescribed MDIs (Ventolin, Symbicort, Flovent & generics). Dual MEMS microphones measure inspiratory flow rate, canister shake duration, and coordination—syncing via low-power LTE-M cellular with zero smartphone pairing required.
Correlates subtle nocturnal rescue-inhaler micro-spikes with hyper-local PM2.5 air quality, pollen, humidity, and behavioral triggers (hydration, reflux/GERD, nutrition) to alert clinicians and coach patients via WhatsApp/SMS days before an acute crisis.
Pushes HL7/FHIR exception alerts directly into Epic and Cerner. Automatically tracks the 16-day monthly telemetry threshold and clinician review logs for Medicare & Commercial CPT codes 98975, 98976, 98980, and 98981.
Patients never pay out-of-pocket for MDI Bridge. Whether you manage a Pulmonology / Allergy Clinic billing Remote Therapeutic Monitoring (RTM) codes or a Health Insurer / Hospital System preventing $15,000 ICU admissions, test our transparent economics below.
Want a customized financial model for your hospital group or health plan?
Schedule Clinical Demo →We believe in radical transparency for customers and prospective investors. Every milestone below clearly distinguishes what our founding team has already built with zero institutional capital versus our upcoming funded targets.
Engineered modular mechanical housing compatible with standard pressurized MDI canisters and validated dual-microphone acoustic signal capture on benchtop respiratory simulators.
Trained lightweight spectral neural network distinguishing propellant actuation clicks from true inspiratory laminar/turbulent flow and canister shaking duration with 94.2% lab accuracy.
Built cloud telemetry ingestion pipeline with automated 16-day CPT 98976 compliance tracking, environmental AQI/pollen API fusion, and holistic patient lifestyle trigger logging.
Legally founded and incorporated in February 2026 with a clean 100% founder-held corporate structure, securing mdibridge.com brand IP and uniting US clinical/reimbursement leadership with top Egyptian embedded IoT & AI engineers.
Deploy initial 100 cellular/BLE smart caps across partner pulmonology clinics in the US and Egypt/GCC to validate >80% 6-month adherence capture and zero-friction onboarding.
Complete regulatory listing for medication adherence tracking and lock in contract manufacturing at <$14 unit BOM for our first 10,000 commercial devices.
Publish peer-reviewed clinical evidence demonstrating a 35–50% reduction in acute asthma/COPD ER visits and secure FDA Class II SaMD clearance for 5-day exacerbation alerts.
Scale national US payer mandates, GCC Ministry of Health preventative respiratory programs, and global biopharma clinical trial endpoint partnerships.
Our unfair advantage combines US reimbursement, FDA regulatory, and pulmonary clinical authority with Egypt’s brightest young embedded-IoT, edge-AI, and medical/clinical innovators—delivering Silicon Valley clinical quality at 4x capital efficiency and unlocking both US and MENA/GCC markets.
MDI Bridge has not raised external institutional capital yet. Every architectural milestone to date has been 100% founder-bootstrapped. Click through our 5-stage capital roadmap below to inspect our target rounds, valuation milestones, and clinical unlock criteria.
Whether you are a pulmonology clinic looking to unlock turnkey RTM reimbursement, a health insurer or hospital group aiming to slash respiratory ER admissions, or a strategic angel/VC investor exploring our inaugural Pre-Seed round, reach our leadership directly.
Boston / Cambridge MedTech Corridor, MA — Regulatory, Payer Reimbursement & US Clinical Trials
us-partners@mdibridge.comCairo & Smart Village Innovation Park, Egypt — Acoustic ML, IoT Firmware, Lifestyle Coaching & MENA Hospital Pilots
rd-mena@mdibridge.comRequest Pre-Seed Data Room, Provisional Patent Summary & Live Hardware Telemetry Demo
investors@mdibridge.comChoose your profile so we route your inquiry directly to the right co-founder.